Mu-Sen Liu
Head Biochemist & Senior Scientist Tango Therapeutics
Seminars
Thursday 22nd October 2026
Mass Spectrometry-Based Kinetic & Site-Specific Profiling of Covalent Inhibitors Targeting VRK1
11:00 am
- VRK1 is a synthetic lethality defined target in VRK2-low cancers
- Presenting our strategy for inhibitor discovery that utilized a focused covalent library, intact protein MS, and cellular cysteine mapping
- Demonstrating that mass spectrometry–based profiling can effectively identify covalent, isoform-selective inhibitors of VRK1
